翟爱东

[關键词] 复方芩兰口服液;急性上呼吸道感染;CRP;IL-6

[中图分类号] R259.62          [文献标识码] A          [文章编号] 1673-9701（2021）14-0036-03

Effect of compound qinlan oral liquid on inflammatory factors in patients with acute upper respiratory tract infection

ZHAI Aidong

The First Department of Internal Medicine， Zibo Maternal and Child Health Hospital， Shandong， Zibo   255000， China

[Abstract] Objective To analyze the effect of compound qinlan oral liquid on inflammatory factors in patients with acute upper respiratory tract infection（AURI）. Methods 130 patients with AURI admitted to Zibo Maternal and Child Health Hospital from August 2019 to August 2020 were selected. They were randomly divided into the observation group （n=65） and the control group （n=65）. The observation group was treated with conventional western medicine combined with compound qinlan oral liquid， while the control group was treated with conventional western medicine. The clinical efficacy， changes of inflammatory factor level before and after treatment， symptom improvement time （cough， fever and pharyngeal pain） and the incidence rate of adverse reactions of the two groups were compared. Results The total effective rate was significantly higher in the observation group than that in the control group （95.4% vs 80.0%， P< 0.05）. There were no significant differences in CRP and IL-6 levels between the two groups before treatment （12.3±3.2 vs 12.2±3.4， P>0.05; 5.6±1.2 vs 5.8±1.4， P>0.05）. After treatment， the levels of CRP and IL-6 were significantly lower in the observation group than those in the control group （3.2±1.0 vs 7.5±2.1， P<0.05; 1.4±0.3 vs 2.3±0.4， P<0.05）. The time to improve cough， fever and pharyngeal pain was shorter in the observation group than that in the control group （1.68±0.24 vs 2.53±0.37， P<0.05; 1.26±0.13 vs 1.94±0.07， P<0.05; 1.44±0.36 vs 2.74±0.63， P<0.05）. The incidence of adverse reactions was 3.08% and 4.62% in the control group and the observation group， respectively， and there was no significant difference between the two groups （P>0.05）. Conclusion Compound qinlan oral liquid can improve the clinical efficacy， reduce the levels of serum inflammatory factors， shorten the time of symptom improvement， and reduce the incidence of adverse reactions of patients with AURI， which is worthy of popularization and application.

[Key words] Compound qinlan oral liquid;Acute upper respiratory tract infection; CRP; IL-6

急性上呼吸道感染是指由于病毒和细菌感染引起的鼻腔、咽喉部急性炎症性疾病，其中约有70%患者由病毒感染引起[1]。急性上呼吸道感染发病可在任何季节发病，且以春季、冬季发病率最高。急性上呼吸道感染患者临床以流涕、咳嗽、咽痛等为主要症状，严重患者还存在发热、疲劳、头痛等症状。此外，临床发现部分患者表现为食欲下降、腹泻等消化道症状[2-3]，对患者的正常工作和生活造成一定影响，因此需要尽早采取有效的治疗措施[4-5]。临床治疗中目前主要是采取抗病毒治疗为主，但仍有部分患者的症状缓解速度较慢，且长期应用抗生素治疗，患者容易出现依赖性，效果不理想[6-7]。复方芩兰口服液是一种中成药，在该病治疗中具有较高的疗效与安全性。为了进一步缩短患者的病程，改善患者的预后情况，本研究主要针对复方芩兰口服液的临床疗效展开分析，现报道如下。

1 资料与方法

1.1临床资料

选取2019年8月至2020年8月130例淄博市妇幼保健院收治急性上呼吸道感染患者，其中男72例，女58例;年龄18～72岁，平均（48.6±8.6）岁。入选标准：①符合《内科学》中关于急性上呼吸道感染的诊断标准;②年龄≥18岁;③均经患者知情同意[8]。排除标准：①其他原因引起的咽痛、发热、咳嗽症状患者;②妊娠期女患者;③合并严重心肺肝肾器质性疾病的患者[9]。根据患者治疗方案的不同将患者随机分为观察组（采取常规西药联合复方芩兰口服液治疗，共计65例）与对照组（采取常规西药治疗，共计65例）。对……